BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23805214)

  • 1. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.
    Kamada Y; Akita M; Takeda Y; Yamada S; Fujii H; Sawai Y; Doi Y; Asazawa H; Nakayama K; Mizutani K; Fujii H; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    PLoS One; 2013; 8(6):e66328. PubMed ID: 23805214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
    Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
    Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis.
    Kamada Y; Fujii H; Fujii H; Sawai Y; Doi Y; Uozumi N; Mizutani K; Akita M; Sato M; Kida S; Kinoshita N; Maruyama N; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    Proteomics Clin Appl; 2013 Oct; 7(9-10):648-56. PubMed ID: 23775887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.
    Tawara S; Tatsumi T; Iio S; Kobayashi I; Shigekawa M; Hikita H; Sakamori R; Hiramatsu N; Miyoshi E; Takehara T
    PLoS One; 2016; 11(3):e0151828. PubMed ID: 27002630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development.
    Asazawa H; Kamada Y; Takeda Y; Takamatsu S; Shinzaki S; Kim Y; Nezu R; Kuzushita N; Mita E; Kato M; Miyoshi E
    Clin Chem Lab Med; 2015 Jan; 53(1):95-102. PubMed ID: 25060348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis.
    Ueda M; Kamada Y; Takamatsu S; Shimomura M; Maekawa T; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kobayashi Y; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
    Pancreatology; 2016; 16(2):238-43. PubMed ID: 26897254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a novel lectin-antibody ELISA system to determine core-fucosylated haptoglobin.
    Shimomura M; Nakayama K; Azuma K; Terao N; Nishino K; Takamatsu S; Nakano M; Takahashi S; Kobayashi Y; Murata K; Kamada Y; Miyoshi E
    Clin Chim Acta; 2015 Jun; 446():30-6. PubMed ID: 25861849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis.
    Morishita K; Ito N; Koda S; Maeda M; Nakayama K; Yoshida K; Takamatsu S; Yamada M; Eguchi H; Kamada Y; Miyoshi E
    Clin Chim Acta; 2018 Dec; 487():84-89. PubMed ID: 30189188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer.
    Fujita K; Shimomura M; Uemura M; Nakata W; Sato M; Nagahara A; Nakai Y; Takamatsu S; Miyoshi E; Nonomura N
    Prostate; 2014 Jul; 74(10):1052-8. PubMed ID: 24802742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer.
    Takeda Y; Shinzaki S; Okudo K; Moriwaki K; Murata K; Miyoshi E
    Cancer; 2012 Jun; 118(12):3036-43. PubMed ID: 22006099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
    Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
    BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis.
    Mi YJ; Zhang Z; Jin SL; Yan HM; Yang XM; Zhao J; Liu RX; Wu Y
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1052-1059. PubMed ID: 38375710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions.
    Kamada Y; Kinoshita N; Tsuchiya Y; Kobayashi K; Fujii H; Terao N; Kamihagi K; Koyama N; Yamada S; Daigo Y; Nakamura Y; Taniguchi N; Miyoshi E
    Clin Chim Acta; 2013 Feb; 417():48-53. PubMed ID: 23262369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
    Ogawa K; Kobayashi T; Furukawa JI; Hanamatsu H; Nakamura A; Suzuki K; Kawagishi N; Ohara M; Umemura M; Nakai M; Sho T; Suda G; Morikawa K; Baba M; Furuya K; Terashita K; Kobayashi T; Onodera M; Horimoto T; Shinada K; Tsunematsu S; Tsunematsu I; Meguro T; Mitsuhashi T; Hato M; Higashino K; Shinohara Y; Sakamoto N
    Sci Rep; 2020 Jan; 10(1):321. PubMed ID: 31941930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of an antibody specific for cancer-associated haptoglobin: a possible implication of clinical investigation.
    Nishino K; Koda S; Kataoka N; Takamatsu S; Nakano M; Ikeda S; Kamamatsu Y; Morishita K; Moriwaki K; Eguchi H; Yamamoto E; Kikkawa F; Tomita Y; Kamada Y; Miyoshi E
    Oncotarget; 2018 Feb; 9(16):12732-12744. PubMed ID: 29560105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.